Gene Dose of Apolipoprotein E Type 4 Allele and the Risk of Alzheimer's Disease in Late Onset Families
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The apolipoprotein E type 4 allele ( APOE -ε4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE -ε4 alleles in 42 families with late onset AD. Thus APOE -ε4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE -ε4 was virtually sufficient to cause AD by age 80.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Compared to the most common APOE3/3 genotype, each additional copy of the APOE4 allele is associated with a higher risk of Alzheimer’s dementia and a younger mean age at dementia onset, such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“such that APOE4 homozygotes are at the highest risk”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [3]
91 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,234
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationMiller, R. G. (1981) · Cited by 3,336
Regression analysis of multivariate incomplete failure time data by modeling marginal distributions
Wei, L. J., Lin, D. Y., & Weissfeld, L. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478873 · Cited by 1,868
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citationNamba, Y., Tomonaga, M., Kawasaki, H., Otomo, E., & Ikeda, K. (1991) · Brain Research · doi:10.1016/0006-8993(91)91092-f · Cited by 1,157
Genetic Linkage Evidence for a Familial Alzheimer's Disease Locus on Chromosome 14
Schellenberg, G. D., Bird, T. D., Wijsman, E. M., Orr, H. T., Anderson, L., Nemens, E., White, J. A., Bonnycastle, L., Weber, J. L., Alonso, M. E., et al. (1992) · Science · doi:10.1126/science.1411576 · Cited by 946
Research works printed but not linked: 3
- SAS/STAT User's Guide Release 6.03 Edition (1988).
- SAS User's Guide: Statistics Version 5 Edition (1985).
- 10.1073/pnas.90.5.1977 · DOI · Paper page
Cited by
Items 1,301–1,400 of 1,689
Disentangling the effects of age and APOE on neuropathology and late life cognitive decline
Yu, L., Boyle, P. A., Leurgans, S., Schneider, J. A., & Bennett, D. A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.074 · Cited by 71
“Older age and apolipoprotein E (APOE) are the 2 most robust risk factors for late life cognitive decline, MCI, and dementia (Corder et al., 1993; Dubé et al., 2013; Evans et al., 1989; Karlamangla et al., 2009; Lipnicki et al., 2013).”
BackgroundAssociation of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021) · Neurology · doi:10.1212/wnl.0000000000011883 · Cited by 71
Bien-Ly, N., Andrews-Zwilling, Y., Xu, Q., Bernardo, A., Wang, C., & Huang, Y. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018381108 · Cited by 71
CSF Apo-E levels associate with cognitive decline and MRI changes
Initiative, F. T. A. D. N., Toledo, J. B., Da, X., Weiner, M. W., Wolk, D. A., Xie, S. X., Arnold, S. E., Davatzikos, C., Shaw, L. M., & Trojanowski, J. Q. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1236-0 · Cited by 71
“There are consistent results of APOE ε4 presence being associated with an earlier age of onset of AD [8]; however, the association with cognitive decline is inconsistent across different studies [5, 9, 61, 64].”
Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2.
Wijsman, E. M., Daw, E. W., Yu, C.-E., Payami, H., Steinbart, E. J., Nochlin, D., Conlon, E. M., Bird, T. D., & Schellenberg, G. D. (2004) · The American Journal of Human Genetics · doi:10.1086/423393 · Cited by 71
“1993), but the high-risk 4 allele is neither necessary nor sufficient to cause disease (Corder et al. 1993; Strittmatter et al. 1993).”
BackgroundAPOE ε4 influences the manifestation of Alzheimer's disease in adults with Down's syndrome
Deb, S., Braganza, J., Norton, N., Williams, H., Kehoe, P. G., Williams, J., & Owen, M. J. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.5.468 · Cited by 71
Longitudinal modeling of cognitive aging and the TOMM40 effect
Caselli, R. J., Dueck, A. C., Huentelman, M. J., Lutz, M. W., Saunders, A. M., Reiman, E. M., & Roses, A. D. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.11.006 · Cited by 69
“This association has been replicated many times since the original reports in the early 1990s [10].”
BackgroundResultRoses, A., Sundseth, S., Saunders, A., Gottschalk, W., Burns, D., & Lutz, M. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.015 · Cited by 70
“97% of Caucasians, connecting the clinical phenotype of AD to APOE genotypes, as was reported in 1993 [2,12].”
Self-citationLicastro, F., Mallory, M., Hansen, L. A., & Masliah, E. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00096-4 · Cited by 70
KLOTHO heterozygosity attenuates APOE4 -related amyloid burden in preclinical AD
Erickson, C. M., Schultz, S. A., Oh, J. M., Darst, B. F., Ma, Y., Norton, D., Betthauser, T., Gallagher, C. L., Carlsson, C. M., Bendlin, B. B., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007323 · Cited by 70
“Our key finding is that KL-VS heterozygosity attenuates the effect of APOE4 on Aβ deposition, suggesting that KL-VS heterozygosity potentially alters APOE4-associated differences in disease pathology, thus conferring resilience to APOE4-linked pathways to disease onset in AD.”
BackgroundResultInfluentialMartiskainen, H., Viswanathan, J., Nykänen, N.-P., Kurki, M., Helisalmi, S., Natunen, T., Sarajärvi, T., Kurkinen, K. M. A., Pursiheimo, J.-P., Rauramaa, T., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.003 · Cited by 70
“Conversely, APOE ε4 is the most prominent genetic factor in AD increasing the risk on average 4-fold (Corder et al., 1993; Strittmatter et al., 1993) and recent genome-wide association studies have identified several new risk loci with small effect sizes (Antunez et al.”
BackgroundGylys, K. H., Fein, J. A., Tan, A. M., & Cole, G. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01643.x · Cited by 70
Thal, D. R., Schultz, C., Botez, G., Del Tredici, K., Mrak, R. E., Griffin, W. S. T., Wiestler, O. D., Braak, H., & Ghebremedhin, E. (2005) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2005.00635.x · Cited by 69
Tsuang, D., Kukull, W., Sheppard, L., Barnhart, R. L., Peskind, E., Edland, S. D., Schellenberg, G., Raskind, M., & Larson, E. B. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01836.x · Cited by 69
Fu, Y., Zhao, J., Atagi, Y., Nielsen, H. M., Liu, C.-C., Zheng, H., Shinohara, M., Kanekiyo, T., & Bu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0099-y · Cited by 69
“The ε4 allele of the APOE gene encoding the apolipoprotein E (apoE) protein strongly influences AD risk and age of onset [8, 9]; risk increases significantly in individuals carrying one copy (ε2/ε4, OR 2.”
BackgroundJackson, R. J., Rose, J., Tulloch, J., Henstridge, C., Smith, C., & Spires-Jones, T. L. (2019) · Brain Communications · doi:10.1093/braincomms/fcz003 · Cited by 69
“shown to increase the risk of Alzheimer’s disease in a dose-dependent manner when compared with the more common APOE3 allele whereas the rarer APOE2 allele is protective (Corder et al., 1993; Corder and Roses, 1996).”
BackgroundResultMidlife lipid and glucose levels are associated with Alzheimer's disease
Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12641 · Cited by 65
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice
Fitz, N. F., Wolfe, C. M., Playso, B. E., Biedrzycki, R. J., Lu, Y., Nam, K. N., Lefterov, I., & Koldamova, R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00394-4 · Cited by 68
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
“On the other hand, apolipoprotein E4 allele (apoE4) is the main genetic risk factor for late-onset AD [42] and it confers a greater AD risk with earlier age of onset (reviewed in [43]).”
BackgroundBloch, L., Friedrich, C. M., & Initiative, F. T. A. D. N. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00879-4 · Cited by 68
Cognitive debt and Alzheimer’s disease
Marchant, N. L., & Howard, R. J. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141515 · Cited by 68
“The 4 allele delivers the greatest known genetic risk for sporadic AD [138], however because 4-allele possession is not deterministic, lifestyle is one possible mediator of its effect.”
BackgroundKawano, M., Kawakami, M., Otsuka, M., Yashima, H., Yaginuma, T., & Ueki, A. (1995) · Clinica Chimica Acta · doi:10.1016/0009-8981(95)06115-t · Cited by 68
Chen, Y., Chen, K., Zhang, J., Li, X., Shu, N., Wang, J., Zhang, Z., & Reiman, E. M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.302 · Cited by 67
“It was reported that the e4 allele has a dose effect on AD risk (Corder et al, 1993).”
BackgroundBennett, C., Crawford, F., Osborne, A., Diaz, P., Hoyne, J., Lopez, R., Roques, P., Duara, R., Rossor, M., & Mullan, M. (1995) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320600102 · Cited by 67
Alzheimer's disease: Innate immunity gone awry?
VanItallie, T. B. (2017) · Metabolism · doi:10.1016/j.metabol.2017.01.014 · Cited by 67
The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
The Association−Dissociation Behavior of the ApoE Proteins: Kinetic and Equilibrium Studies
Garai, K., & Frieden, C. (2010) · Biochemistry · doi:10.1021/bi101407m · Cited by 67
Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease
Xia, Z., Prescott, E. E., Urbanek, A., Wareing, H. E., King, M. C., Olerinyova, A., Dakin, H., Leah, T., Barnes, K. A., Matuszyk, M. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49028-z · Cited by 67
“Compared to the most common APOE3 form, APOE2 isneuroprotective 2 ,while APOE4 increasesADrisk; APOE4 homozygotes are 15-fold more susceptible to AD than APOE3 homozygotes 3 – 5 , and disease begins several years earlier in APOE4 carriers than those with APOE3 or APOE2 3 .”
BackgroundKlein, R. C., Mace, B. E., Moore, S. D., & Sullivan, P. M. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.10.027 · Cited by 67
“, 1993) (Corder et al., 1993).”
Frieser, M. J., Wilson, S., & Vrieze, S. (2018) · Health Psychology · doi:10.1037/hea0000683 · Cited by 67
Zhao, J., Fu, Y., Liu, C.-C., Shinohara, M., Nielsen, H. M., Dong, Q., Kanekiyo, T., & Bu, G. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.526095 · Cited by 67
“ApoE and A bind to each other and also to their common receptors, including LRP1, LDLR, and heparan sulfate proteoglycan (11, 12).”
BackgroundInfluentialThe generation and function of soluble apoE receptors in the CNS
Rebeck, G. W., LaDu, M. J., Estus, S., Bu, G., & Weeber, E. J. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-15 · Cited by 66
“APOE-ε2 is associated with reduced odds and delayed onset of AD while APOE-ε4 is associated with increased odds and earlier onset of AD [3].”
Mukhopadhyay, S., & Banerjee, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215065 · Cited by 66
“Similar evidence is also provided by the APOE mutations [16].”
Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models
Franklin, H., Clarke, B. E., & Patani, R. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101973 · Cited by 66
“Many of the GWAS-identified loci that confer genetic risk for late-onset AD are highly expressed in astrocytes and microglia, with the first identified and most studied being the APOE4 allele of the polymorphic APOE4 gene (Corder et al., 1993).”
Watanabe, Y., Kitamura, K., Nakamura, K., Sanpei, K., Wakasugi, M., Yokoseki, A., Onodera, O., Ikeuchi, T., Kuwano, R., Momotsu, T., et al. (2016) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000442585 · Cited by 65
Cao, Y., Zhao, L.-W., Chen, Z.-X., & Li, S.-H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1430465 · Cited by 65
Relation of genomic variants for Alzheimer disease dementia to common neuropathologies
Farfel, J. M., Yu, L., Buchman, A. S., Schneider, J. A., De Jager, P. L., & Bennett, D. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002909 · Cited by 64
Genetics of Alzheimer’s disease: An East Asian perspective
Miyashita, A., Kikuchi, M., Hara, N., & Ikeuchi, T. (2023) · Journal of Human Genetics · doi:10.1038/s10038-022-01050-z · Cited by 64
“In the 1970s and 1980s, genetic research on APOE was mainly conducted from the viewpoint of dyslipidemia, and it was in the 1990s that it was reported that APOE genotypes confer major risk of AD [9].”
BackgroundAPOE and dementia – resequencing and genotyping in 105,597 individuals
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12165 · Cited by 64
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
Chauhan, N. B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.r300010-jlr200 · Cited by 64
Maloney, B., Ge, Y., Alley, G. M., & Lahiri, D. K. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04831.x · Cited by 63
“Individuals in industrialized societies, who have at least one copy of this allele, have an earlier age of onset in addition to increased risk of developing AD (Corder et al. 1993).”
BackgroundCambon, K., Davies, H. A., & Stewart, M. G. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00065-8 · Cited by 63
Capillary CAA and perivascular Aβ-deposition: Two distinct features of Alzheimer's disease pathology
Attems, J., Yamaguchi, H., Saido, T. C., & Thal, D. R. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.030 · Cited by 63
“Apolipoprotein E (apoE) is involved in physiological perivascular clearance of the extracellular fluid [13] and its APOE ε4 allele has been reported to be a major risk factor for sporadic AD [14,15].”
APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease
Quiroz, Y. T., Aguillon, D., Aguirre-Acevedo, D. C., Vasquez, D., Zuluaga, Y., Baena, A. Y., Madrigal, L., Hincapié, L., Sanchez, J. S., Langella, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2308583 · Cited by 63
Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease
Pereira, H. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00118-2 · Cited by 62
RAB10: an Alzheimer’s disease resilience locus and potential drug target
Tavana, J., Rosene, M., Jensen, N., Ridge, P. G., Kauwe, J. S. K., & Karch, C. M. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159148 · Cited by 62
“Risk for developing AD is 3-fold higher in individuals carrying one copy of the ε4 allele and 12-fold higher in individuals carrying 2 copies of APOE ε4.(16) Conversely, APOE ε2 confers resilience to AD, while the ε3 allele is considered neutral risk.”
Genetic variation in APOE cluster region and Alzheimer's disease risk
Cervantes, S., Samaranch, L., Vidal-Taboada, J. M., Lamet, I., Bullido, M. J., Frank-García, A., Coria, F., Lleó, A., Clarimón, J., Lorenzo, E., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.023 · Cited by 62
Hirsch-Reinshagen, V., & Wellington, C. L. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32813aeabf · Cited by 61
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Staurenghi, E., Cerrato, V., Gamba, P., Testa, G., Giannelli, S., Leoni, V., Caccia, C., Buffo, A., Noble, W., Perez-Nievas, B. G., et al. (2021) · Redox Biology · doi:10.1016/j.redox.2020.101837 · Cited by 60
Weigand, A. J., Thomas, K. R., Bangen, K. J., Eglit, G. M. L., Delano‐Wood, L., Gilbert, P. E., Brickman, A. M., Bondi, M. W., & Initiative, F. T. A. D. N. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12173 · Cited by 59
“1,2 Most researchonmechanismsunderlyingAPOE ε 4alleliceffectshasfocused on the role of pathologic amyloid beta 1-42 (A β ), demonstrating that APOEisoformsareinvolvedintheoligomerization,aggregation,degradation, and clearance of A β , 3,4 and that ε 4-carriers have increased incidence of A β…”
Pharmacological modulation of autophagy for Alzheimer's disease therapy: Opportunities and obstacles
Deng, Z., Dong, Y., Zhou, X., Lu, J.-H., & Yue, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.12.009 · Cited by 58
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
“Apolipoprotein E (ApoE) ε4 carrier status—ApoE genotype is a well described genetic risk factor for AD [12].”
A role of low-density lipoprotein receptor-related protein 4 (LRP4) in astrocytic Aβ clearance
Zhang, H., Chen, W., Tan, Z., Zhang, L., Dong, Z., Cui, W., Zhao, K., Wang, H., Jing, H., Cao, R., et al. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.0250-20.2020 · Cited by 58
“, 1995) and ApoE, whose «4 allele is implicated late-onset AD (Corder et al., 1993; Strittmatter et al., 1993a).”
BackgroundHui, L., Chen, X., & Geiger, J. D. (2012) · Life Sciences · doi:10.1016/j.lfs.2012.04.039 · Cited by 58
“People carrying the ApoE4 allele have an increased risk of developing AD (Corder et al., 1993; Wisdom et al., 2011) and have elevated levels of plasma cholesterol (Corder et al., 1993; Marzolo and Bu, 2009).”
InfluentialDengler-Crish, C. M., Ball, H. C., Lin, L., Novak, K. M., & Cooper, L. N. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.03.021 · Cited by 58
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 74
“Inheritance of the APOE ε4 allele is the strongest known risk factor for sporadic AD and shows directs association with increased Aβ plaque load and reduced age of disease onset [6-8].”
BackgroundApolipoprotein E ε4 Allele Is Associated with Vascular Dementia
Baum, L., Lam, L. C. W., Kwok, T., Lee, J., Chiu, H. F. K., Mok, V. C. T., Wong, A., Chen, X., Cheung, W. S., Pang, C. P., et al. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000095246 · Cited by 57
“Apolipoprotein E (ApoE) is a 299 amino acid protein with 3 common isoforms encoded by alleles e2, e3 and e4, reflecting a polymorphism at 2 sites on exon 4. The e4 allele of ApoE is associated with an increased risk and earlier onset of AD [”
Proitsi, P., Lee, S. H., Lunnon, K., Keohane, A., Powell, J., Troakes, C., Al-Sarraj, S., Furney, S., Soininen, H., Kłoszewska, I., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.08.002 · Cited by 57
Garai, K., Baban, B., & Frieden, C. (2011) · Biochemistry · doi:10.1021/bi1020106 · Cited by 57
Neitzel, J., Franzmeier, N., Rubinski, A., Dichgans, M., Brendel, M., (ADNI), A. D. N. I., Weiner, M., Aisen, P., Petersen, R., Jack, C. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23755-z · Cited by 57
Reynolds, C. A., Hong, M.-G., Eriksson, U. K., Blennow, K., Wiklund, F., Johansson, B., Malmberg, B., Berg, S., Alexeyenko, A., Grönberg, H., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq079 · Cited by 57
Population-based analysis of Alzheimer’s disease risk alleles implicates genetic interactions.
Ebbert, M. T. W., Ridge, P. G., Wilson, A. R., Sharp, A. R., Bailey, M., Norton, M. C., Tschanz, J. T., Munger, R. G., Corcoran, C. D., & Kauwe, J. S. K. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.008 · Cited by 57
Impact of COVID-19 on Alzheimer’s Disease Risk: Viewpoint for Research Action
Abate, G., Memo, M., & Uberti, D. (2020) · Healthcare · doi:10.3390/healthcare8030286 · Cited by 56
“with two copies of APOE3, while one copy of APOE4 increases the chance of AD by three times and lowers the average age of onset to 76 years [79].”
BackgroundLodato, M. A., & Walsh, C. A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz191 · Cited by 56
“More commonly, dosage of the APOE ε4 allele confers significantly increased risk of the disease (67).”
BackgroundThe Dominantly Inherited Alzheimer Network (DIAN), Li, Z., Del-Aguila, J. L., Dube, U., Budde, J., Martinez, R., Black, K., Xiao, Q., Cairns, N. J., Dougherty, J. D., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0551-4 · Cited by 56
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases
Feringa, F. M., Koppes-den Hertog, S. J., Wang, L. Y., Derks, R. J. E., Kruijff, I., Erlebach, L., Heijneman, J., Miramontes, R., Pömpner, N., Blomberg, N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01365-z · Cited by 56
“https://doi.org/10.1038/s42255-025-01365-z the risk for AD from 3–4-fold (heterozygosity) to 14-fold (homozygo-sity) depending on ethnicity 56,57 , with even higher reported odds ratios in neuropathologically confirmed cases 58 .”
InfluentialJohnson, L. A., Torres, E. R., Weber Boutros, S., Patel, E., Akinyeke, T., Alkayed, N. J., & Raber, J. (2019) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17746186 · Cited by 56
Sorting receptor sortilin—a culprit in cardiovascular and neurological diseases
Carlo, A.-S., Nykjaer, A., & Willnow, T. E. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1152-3 · Cited by 56
“Multiple mechanisms affect the concentration of Aβ in the brain interstitial fluid (ISF) including binding of this peptide to apoE, the major apolipoprotein in the brain and the most important genetic risk factor of sporadic AD [45].”
BackgroundFujiyoshi, M., Ohtsuki, S., Hori, S., Tachikawa, M., & Terasaki, T. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04240.x · Cited by 56
“Isoforms of apoE are one of the risk factors of AD (Corder et al. 1993; Strittmatter et al. 1993), and it has been suggested that cholesterol release from astrocytes is influenced by isoforms of apoE in a study using human apoE knock-in mice under endogenous apoE-deficient conditions (Gong et al.…”
BackgroundAlzheimer disease and the periodontal patient: New insights, connections, and therapies
Ryder, M. I., & Xenoudi, P. (2021) · Periodontology 2000 · doi:10.1111/prd.12389 · Cited by 55
Pedersen, N. L., Posner, S. F., & Gatz, M. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1608 · Cited by 55
Haddick, P. C. G., Alzheimer’s Disease Genetic Consortium (ADGC), A. D. N. I. (., Larson, J. L., Rathore, N., Bhangale, T. R., Phung, Q. T., Srinivasan, K., Hansen, D. V., Lill, J. R., Pericak-Vance, M. A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160524 · Cited by 55
“[26].”
Self-citationApolipoprotein E as a β-amyloid-independent factor in Alzheimer’s disease
Wolf, A. B., Valla, J., Bu, G., Kim, J., LaDu, M., Reiman, E. M., & Caselli, R. J. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt204 · Cited by 57
“The most prevalent and best-established genetic risk factor for late-onset, sporadic AD is APOE, encoding apolipoprotein E (apoE), first described in the early 1990s [1].”
BackgroundLipid metabolism in Alzheimer’s disease
Zhu, T.-B., Zhang, Z., Luo, P., Wang, S.-S., Peng, Y., Chu, S.-F., & Chen, N.-H. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.11.012 · Cited by 55
Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney
MIYATA, T., SUGIYAMA, S., NANGAKU, M., SUZUKI, D., URAGAMI, K.-I., INAGI, R., SAKAI, H., & KUROKAWA, K. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1071590 · Cited by 55
DeMattos, R. B. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:3:255 · Cited by 55
In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS
Wildsmith, K. R., Basak, J. M., Patterson, B. W., Pyatkivskyy, Y., Kim, J., Yarasheski, K. E., Wang, J. X., Mawuenyega, K. G., Jiang, H., Parsadanian, M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038013 · Cited by 58
Liang, T., Hang, W., Chen, J., Wu, Y., Wen, B., Xu, K., Ding, B., & Chen, J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00563-y · Cited by 54
“While individuals carrying apoE ε4 homozygotes have a 12-fold increased risk for AD, those carrying apoE ε4 heterozygotes have a 2- to 3-fold increased risk for AD and the apoE4 reduces the age of AD onset [3].”
BackgroundACAT inhibition and amyloid beta reduction
Bhattacharyya, R., & Kovacs, D. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.04.003 · Cited by 53
Accumulation of amyloid in cognitive impairment after mild traumatic brain injury
Yang, S.-T., Hsiao, I.-T., Hsieh, C.-J., Chiang, Y.-H., Yen, T.-C., Chiu, W.-T., Lin, K.-J., & Hu, C.-J. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.12.032 · Cited by 53
“The apolipoprotein E (APOE) gene contains three genetic polymorphisms (alleles; ε2, 3, 4), and APOE4 has been associated with the increased risk of AD development and earlier onset in a gene-dose dependent manner [15].”
BackgroundVance, J. M., Farrer, L. A., Huang, Y., Cruchaga, C., Hyman, B. T., Pericak‐Vance, M. A., Goate, A. M., Greicius, M. D., Griswold, A. J., Haines, J. L., et al. (2024) · Annals of Neurology · doi:10.1002/ana.26864 · Cited by 52
Self-citationFlowers, S. A., Grant, O. C., Woods, R. J., & Rebeck, G. W. (2020) · Glycobiology · doi:10.1093/glycob/cwz084 · Cited by 52
“Introduction Apolipoprotein E (APOE) is the most significant genetic risk factor for late-onset Alzheimer’s disease (AD), the most common form of AD (Corder et al. 1993; Lambert et al. 2013).”
BackgroundAlzheimer pathology of patients carrying apoliprotein E ε4 allele
Heinonen, O. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00076-q · Cited by 52
Kulminski, A. M., Arbeev, K. G., Culminskaya, I., Arbeeva, L., Ukraintseva, S. V., Stallard, E., Christensen, K., Schupf, N., Province, M. A., & Yashin, A. I. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004141 · Cited by 52
Association of APOE With Primary Open-Angle Glaucoma Suggests a Protective Effect for APOE ε4
Margeta, M. A., Letcher, S. M., Igo, R. P., Cooke Bailey, J. N., Pasquale, L. R., Haines, J. L., Butovsky, O., Wiggs, J. L., & for the NEIGHBORHOOD consortium (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.8.3 · Cited by 51
Self-citationDouble stranded RNA activated EIF2 α kinase (EIF2AK2; PKR) is associated with Alzheimer's disease
Bullido, M. J., Martínez-García, A., Tenorio, R., Sastre, I., Muñoz, D. G., Frank, A., & Valdivieso, F. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.023 · Cited by 51
Chernick, D., Ortiz‐Valle, S., Jeong, A., Swaminathan, S. K., Kandimalla, K. K., Rebeck, G. W., & Li, L. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14554 · Cited by 51
TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity
Maruszak, A., Pepłońska, B., Safranow, K., Chodakowska-Żebrowska, M., Barcikowska, M., & Żekanowski, C. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110743 · Cited by 50
“and its effect is dose-dependent [2, 3].”
Association of African Ancestry–Specific APOE Missense Variant R145C With Risk of Alzheimer Disease
Le Guen, Y., Raulin, A.-C., Logue, M. W., Sherva, R., Belloy, M. E., Eger, S. J., Chen, A., Kennedy, G., Kuchenbecker, L., O’Leary, J. P., et al. (2023) · JAMA · doi:10.1001/jama.2023.0268 · Cited by 50
Prospects for strain-specific immunotherapy in Alzheimer’s disease and tauopathies
Bittar, A., Sengupta, U., & Kayed, R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0046-8 · Cited by 50
“Away from Mendelian genetic mutations in amyloid or tau, apolipoprotein E (APOE) gene was identified to be one of the most compelling risk factors for sporadic AD based on genome-wide association study (GWAS) studies.(50) APOE gene mutation animal models express not only Aβ pathology, but also tau NFTs similar to huma…”
BackgroundBeck, T. N., Nicolas, E., Kopp, M. C., & Golemis, E. A. (2014) · Oncoscience · doi:10.18632/oncoscience.64 · Cited by 50
“APOE LOAD ε4 variant Increased Aβ aggregation and decreased clearance [33-35]”
BackgroundAkram, A., Schmeidler, J., Katsel, P., Hof, P. R., & Haroutunian, V. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.006 · Cited by 50
“All rights reserved and epidemiologic data (Corder et al., 1993; Simons et al., 1998; Fassbender et al., 2001; Refolo et al., 2001; Kivipelto et al., 2001; Shobab et al., 2005; Hutter-Paier et al., 2004; Wolozin et al., 2000; Wahrle et al., 2002).”
Paranjpe, M. D., Belonwu, S., Wang, J. K., Oskotsky, T., Gupta, A., Taubes, A., Zalocusky, K. A., Paranjpe, I., Glicksberg, B. S., Huang, Y., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.735611 · Cited by 49
Wang, Y.-Y., Ge, Y.-J., Tan, C.-C., Cao, X.-P., Tan, L., & Xu, W. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-201606 · Cited by 49
“Prior work has shown that possession of the APOE4 allele is associated with a greater risk of AD dementia [2–5].”
Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease
Wang, J. C., Kwon, J. M., Shah, P., Morris, J. C., & Goate, A. (2000) · Neurology · doi:10.1212/wnl.55.11.1644 · Cited by 49
“Control (%) 34 (6) 444 (81) 70 (13) 548 2 (1) 22 (8) 184 (67) 8 (3) 54 (20) 4 (1) 274”
InfluentialRoberts, J. A., Varma, V. R., An, Y., Varma, S., Candia, J., Fantoni, G., Tiwari, V., Anerillas, C., Williamson, A., Saito, A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi8178 · Cited by 49
Permanne, B., Perez, C., Soto, C., Frangione, B., & Wisniewski, T. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7727 · Cited by 49
Apolipoprotein E isoforms in Alzheimer's disease pathology and etiology
Baum, L., Chen, L., Ng, H.-K., & Pang, C. P. (2000) · Microscopy Research and Technique · doi:10.1002/1097-0029(20000815)50:4<278::aid-jemt5>3.0.co;2-t · Cited by 49
Belin, A. C., Björk, B. F., Westerlund, M., Galter, D., Sydow, O., Lind, C., Pernold, K., Rosvall, L., Håkansson, A., Winblad, B., et al. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.05.010 · Cited by 48
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- University of California, Los Angeles (US)
- Massachusetts General Hospital (US)
- Joseph and Kathleen Bryan Alzheimer's Disease Research Center, Duke University Medical Center, Durham, NC 27710.
- Venue
- Science
- Published
- 1993-08-13
- Volume
- 261
- Issue
- 5123
- Pages
- 921-923
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2036362108
- Cited by
- 9,429
- References
- 16
- Citations by year
- 2026: 289 · 2025: 380 · 2024: 355 · 2023: 328 · 2022: 356 · 2021: 378 · 2020: 396 · 2019: 358 · 2018: 341 · 2017: 343 · 2016: 345 · 2015: 303 · 2014: 343 · 2013: 335 · 2012: 333
- FWCI
- 135.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, gene dosage, Alzheimer's disease, genetic risk, homozygosity, age of onset, genetic association
- MeSH terms
- Aged, Aged, 80 and over, Aging, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Homozygote, Humans, Male, Risk Factors, Linkage Disequilibrium, Survival Rate, Amyloid beta-Peptides, Apolipoprotein E4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.